1
![Modus Therapeutics]()
![Modus Therapeutics]()
![Modus Therapeutics]()
Modus Therapeutics
Leadership team
Dr. John Öhd M.D., Ph.D. (Chief Exec. Officer)
Mr. Claes Lindblad (Chief Financial Officer)
Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical, Therapeutics
Number of Employees
0 - 50
Headquarters
Stockholm, Stockholms Lan, Sweden
Established
2011
Traded as
STO:MODTX
Overview
Location
Summary
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
History
The company was founded in 2013 by a small group of scientists and doctors in Stockholm, Sweden. The mission of Modus Therapeutics is to develop innovative treatments and cures for debilitating rare diseases.
Mission
At Modus Therapeutics, we are focused on creating novel therapies to treat rare diseases and improve patients’ quality of life.
Vision
Modus Therapeutics envisions a world in which all people affected by rare diseases can access effective treatments and quality care.
Key Team
Dr. John Öhd M.D., Ph.D. (Chief Exec. Officer)
Mr. Claes Lindblad (Chief Financial Officer)
Recognition and Awards
Modus Therapeutics has won multiple awards including the “Fortune Tech Champions” award in 2016, and two EY Entrepreneur of the Year awards in 2017.
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Leadership team
Dr. John Öhd M.D., Ph.D. (Chief Exec. Officer)
Mr. Claes Lindblad (Chief Financial Officer)
Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical, Therapeutics
Number of Employees
0 - 50
Headquarters
Stockholm, Stockholms Lan, Sweden
Established
2011
Traded as
STO:MODTX